| HOME >> MEDICINE >> TECHNOLOGY |
AUSTIN, Texas, Aug. 14, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its results for the quarter ended June 30, 2014.
Q2 2014 Key Developments
Q2 2014 Financial Results
Total revenue in the second quarter of 2014 was $324,000, as compared to $323,000 in the same year-ago period. Second quarter 2014 revenue was comprised of $211,000 in OVA1 product revenue and $113,000 in license revenue.
The product revenue in the second quarter of 2014 was derived from 4,223 OVA1 tests performed at the fixed $50 per test. This was consistent with the 4,184 OVA1 tests performed in the same year-ago quarter.
OVA1 product revenue in both the second quarter of 2014 and the year-ago period does not include the additional royalty component of revenue based on 33% of Quest Diagnostics' gross margin. Vermillion will recognize this portion of revenue when it is reported by Quest Diagnostics in an annual 'true-up' expected after the end of the calendar year. The true-up is based on reimbursed and unreimbursed tests for which Quest Diagnostics considers the payment status as final. For the full year of 2013, the true-up provided $1,262,000 in revenue to Vermillion or an additional $75 per test.
Total operating expenses in the second quarter of 2014 increased to $5.8 million from $2.4 million in the year-ago quarter. The increase was primarily due to operational investments including roughly tripling our salesforce in April 2014, opening ASPiRA LABS, and increased research and development to advance our next-generation test as well as CEO severance.
Net loss for the second quarter was $5.6 million or $(0.15) per share, as compared to a net loss of $2.1 million or $(0.11) per share in the year-ago quarter.
As of June 30, 2014, cash and equivalents totaled $22.2 million. The company used $3.8 million in cash for operations in the second quarter of 2014, and expects to utilize $4.5 million to $5.5 million in cash in the third quarter of 2014. The third quarter of 2014 is expected be our high point for cash utilization before normalizing at a lower level beginning in the fourth quarter.
Management Commentary
"In Q2, we reached major milestones on our OVA1 commercialization strategy," said James LaFrance, Vermillion's chairman, president and CEO. "We opened ASPiRA LABS, our own national CLIA certified clinical laboratory for diagnostic processing based near Austin, Texas.
"We also significantly expanded our field sales team in April of this year. We typically see positive results three to six months after adding sales staff. Thus, we expect to see improved test volumes in the second half of the year."
Conference Call and Webcast
Vermillion will hold a conference call to discuss its second quarter results later today, Thursday, August 14, 2014, at 4:30 p.m. Eastern time. Vermillion's Chairman, President and CEO James LaFrance will host the call, followed by a question and answer period.
Date: Thursday, August 14, 2014
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-888-297-0360
International dial-in number: 1-719-325-2306
Conference ID: 7027308
Webcast: http://edge.media-server.com/m/p/7m5vxsyv/lan/en
The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Vermillion at (512) 519-0400.
A replay of the call will be available approximately two hours after the call until August 28, 2014.
Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay ID: 7027308
About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.
The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995 that involve significant risks and uncertainties including statements regarding Vermillion's future revenue, Vermillion's expected cash outlay and future test volumes. Words such as "may," "expects," "intends," "anticipates," "believes," "estimates," "plans," "seeks," "could," "should," "continue," "will," "potential," "projects" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion's expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ from those projected in such forward-looking statements include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products or otherwise comply with applicable laws and regulations; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third-party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty regarding Vermillion's ability to generate sufficient demand for ASPiRA LABS' services to cover the laboratory's operating costs; (7) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (8) other factors that are described in Vermillion's Form 10-K for the year ended December 31, 2013 and Vermillion's Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission (the "SEC"). Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.
Investor Relations Contact:
Eric Schoen
Vice President, Finance and Chief Accounting Officer
Tel 1-512-519-0424
eschoen@vermillion.com
Vermillion, Inc.Consolidated Balance Sheets(Amounts in Thousands, Except Share and Par Value Amounts)
(Unaudited)June 30,December 31,20142013AssetsCurrent assets:Cash and cash equivalents
$
22,186$
29,504Accounts receivable 190373Prepaid expenses and other current assets 719372Total current assets 23,09530,249Property and equipment, net 416391Total assets
$
23,511$
30,640Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable
$
1,264$
541Accrued liabilities 2,0961,283Short-term debt1,1061,106Deferred revenue1,215628Total current liabilities 5,6813,558Deferred revenue88316Total liabilities 5,7693,874Commitments and contingenciesStockholders' equity:Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at June 30, 2014 and December 31, 2013, respectively——Common stock, $0.001 par value, 150,000,000 shares authorized at June 30, 2014 and December 31, 2013; 35,897,776 and 35,825,673 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively3636Additional paid-in capital 359,512358,994Accumulated deficit (341,806)(332,264)Total stockholders' equity17,74226,766Total liabilities and stockholders' equity
$
23,511$
30,640Vermillion, Inc.Consolidated Statements of Operations(Amounts in Thousands, Except Share and Per Share Amounts)
(Unaudited)Three Months Ended June 30, Six Months Ended June 30, 2014201320142013Revenue:Product
$
211$
210$
402$
424License113113227227Total revenue324323629651Cost of revenue:Product 883414371Gross profit236289486580Operating expenses:Research and development(1)1,0575542,2101,038Sales and marketing(2)2,7669204,8701,992General and administrative(3)1,9719342,9592,271Total operating expenses 5,7942,40810,0395,301Loss from operations (5,558)(2,119)(9,553)(4,721)Interest income 126268Other income (expense), net (9)(4)(15)25Net loss
$
(5,555)$
(2,117)$
(9,542)$
(4,688)Net loss per share - basic and diluted
$
(0.15)$
(0.11)$
(0.27)$
(0.27)Weighted average common shares used to compute basic and diluted net loss per common share 35,853,02719,637,16135,840,49117,431,641Non-cash stock-based compensation expense included
in operating expenses:(1) Research and development
$
31$
12$
71$
32(2) Sales and marketing44326986(3) General and administrative29014359121
'/>"/>
| SOURCE Vermillion, Inc. Copyright©2014 PR Newswire. All rights reserved |
Related medicine technology :
1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion to Present at the 2012 Gateway Conference on September 6
7. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
8. Vermillion Reports Third Quarter 2012 Results
9. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |